Skip to content
Clinical Trials – home

Understanding ALLERGEN EXTRACT FROM PHLEUM PRATENSE POLLEN, GLUTARALDEHYDE-MODIFIED: A Promising Treatment for Grass Pollen Allergies

1 / 3
trials open to patients / all trials
2+
Countries

In short

This article discusses clinical trials investigating the use of Allergen Extract from Phleum Pratense Pollen, Glutaraldehyde-Modified, as part of a mixture with other grass and tree pollen extracts for treating allergic rhinitis and asthma. These trials aim to assess the safety and effectiveness of subcutaneous immunotherapy using these modified allergen extracts in patients with moderate to severe allergic symptoms.

At a glance

Study Type
Phase III clinical trials
Design
Prospective, multicentre, randomized, double-blind, placebo-controlled
Treatment
Subcutaneous immunotherapy with polymerized allergen extracts
Allergens
Grass pollen mixture (including Phleum pratense) with either Juniperus oxycedrus or Olea europaea
Target Population
Patients aged 12-65 with moderate-severe allergic rhinitis/rhinoconjunctivitis, with or without mild-moderate asthma
Primary Outcome
Overall symptom and medication scores during relevant pollen seasons
Secondary Outcomes
Symptom-free days, medication-free days, quality of life, immunological parameters, safety assessments
Treatment Duration
Up to 12 months
Maximum Dose
0.5 ml daily

What is ALLERGEN EXTRACT FROM PHLEUM PRATENSE POLLEN, GLUTARALDEHYDE-MODIFIED?

ALLERGEN EXTRACT FROM PHLEUM PRATENSE POLLEN, GLUTARALDEHYDE-MODIFIED is a specialized allergy treatment derived from timothy grass (Phleum pratense) pollen. This extract is chemically modified using glutaraldehyde, a process that alters the structure of the allergens to make them less reactive while still maintaining their ability to stimulate the immune system.

How Does It Work?

This modified allergen extract works through a process called immunotherapy. By introducing small amounts of the modified allergen into your body over time, your immune system gradually becomes less sensitive to the actual grass pollen allergens. This can lead to reduced allergic reactions when you're exposed to grass pollen in your environment.

Medical Conditions Treated

The primary conditions treated with this allergen extract include:

  • Allergic rhinitis (hay fever): Inflammation of the nasal passages causing symptoms like sneezing, runny nose, and nasal congestion
  • Allergic rhinoconjunctivitis: A combination of nasal and eye symptoms caused by allergies
  • Mild to moderate allergic asthma: Breathing difficulties triggered by allergens

These conditions can range from intermittent (occurring occasionally) to persistent (ongoing) and from moderate to severe in intensity.

How Is It Administered?

The allergen extract is administered as a subcutaneous injection, which means it's injected just under the skin. Treatment typically involves a series of injections over time, with the dose gradually increasing to build up tolerance.

Current Clinical Trials

As of now, there are ongoing clinical trials to further evaluate the efficacy and safety of this treatment. These trials are focusing on its use in combination with other allergen extracts, such as those from olive tree pollen or Juniperus oxycedrus (prickly juniper) pollen.

Efficacy and Safety

The main objective of the current clinical trials is to assess how well this treatment works compared to a placebo in reducing allergy symptoms and medication use. Researchers are also closely monitoring its safety profile. The trials are measuring various outcomes, including:

  • Overall symptom and medication scores during pollen seasons
  • Number of symptom-free and medication-free days
  • Frequency of asthma exacerbations
  • Changes in quality of life
  • Changes in immunological markers (like IgE and IgG4 antibodies)

These measurements will help determine how effective the treatment is in real-world conditions.

Who Is Eligible for This Treatment?

While individual cases may vary, general eligibility criteria for this treatment include:

  • Age between 12 and 65 years
  • Confirmed history of grass pollen allergy
  • Positive skin prick test or specific IgE test for grass pollen
  • Moderate to severe allergy symptoms not adequately controlled by standard medications

It's important to note that this treatment may not be suitable for everyone, particularly those with severe asthma, certain autoimmune conditions, or other specific health issues.

Potential Side Effects

As with any medical treatment, there can be side effects. Common reactions may include:

  • Local reactions at the injection site (redness, swelling, itching)
  • Mild allergic symptoms (sneezing, runny nose)

In rare cases, more severe allergic reactions can occur. That's why this treatment is always administered under medical supervision, and patients are monitored after each injection.

Remember, if you think you might benefit from this treatment, it's essential to discuss it with your allergist or healthcare provider. They can provide personalized advice based on your specific allergy profile and medical history.

Questions people often ask

Conditions where Allergen Extract From Phleum Pratense Pollen, Glutaraldehyde-Modified is being studied

Each condition opens its own overview and trial list

Trials with Allergen Extract From Phleum Pratense Pollen, Glutaraldehyde-Modified

Recruiting trials first

See all 3 →
Quick filters
  • Participants:All ages
  • Participants:Adults
  • Participants:All ages
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).